China'a New Drug Approvals: Year in Review 2019

CPhI & P-MEC China provides you with the latest report exploring how China's new drug approval keeps in a sustained momentum.

webversion China's New Drug Approvals Our latest report published in partnership with GBI Health explores how reforms to China's drug approval channels introduced in 2015 have resulted in a sustained momentum in new drug approvals, with at least 40 first-time market entrants gaining authorisation each year after 2016. We discover how last year, a total of 61 molecules not previously available on the market were cleared for entry, comprised of 57 'Western' medicine and 4 traditional Chinese medicines (TCMs).  Get Your Free Report Want to Learn More about the Chinese Pharma Market?  Join us at CPhI & P-MEC China 2020 offline show during 16-18 December in Shanghai, where 100+ conferences and activities will be held. You'll have the chance to meet China's pharma experts and industry insiders who can share their first-hand knowledge, while learning from a comprehensive educational programme.  Register Now for Free to Save CNY100 CPhI & P-MEC China is also keeping you informed of the latest industry trends in China and connected with the entire pharmaceutical industries online via E-trade Season.  Stay tuned with us in September for "Popular Natural Extracts for Health and Pharma" and in October for "P-MEC China Webinar on Pharmaceutical Manufacturing and Technologies"!  Check More on E-trade Season >> CPhI & P-MEC China 2020 16-18 December 2020 | SNIEC, Shanghai, China Website Register unsubscribe News